Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today.
Total revenue dropped to $344 million from $4.7 billion in the same period last year, mainly due to a decrease in sales of the company’s COVID-19 vaccine.
Net loss was $1.4 billion, or $3.62 per share, compared to net income of $2.2 billion, or $5.24 per share, last year.
Product sales were $293 million, down 94% compared to last year, mainly due to lower sales volume. The company reported $0.3 billion in COVID-19 vaccine sales in Q2.
For FY2023, the company is expecting COVID-19 sales of $6-8 billion, dependent on US vaccination rates.
Most Popular
United Airlines (UAL) Earnings: 4Q24 Key Numbers
United Airlines (NASDAQ: UAL) reported total operating revenue of $14.7 billion for the fourth quarter of 2024, up 7.8% compared to the same period last year. Net income increased 64%
Highlights of Abbott Laboratories (ABT) Q4 2024 results
Abbott Laboratories (NYSE: ABT) on Wednesday announced financial results for the fourth quarter of 2024, reporting an increase in sales and adjusted profit. Total reported sales increased 7.2% year-over-year to
PG Earnings: Key quarterly highlights from Procter & Gamble’s Q2 2025 financial results
The Procter & Gamble Company (NYSE: PG) reported its second quarter 2025 earnings results today. Net sales were $21.9 billion, up 2% from the prior-year quarter. Organic sales increased 3%.